Uremic pruritus

Professor Lars Iversen joins MC2 Therapeutics as new Chief Medical Officer

Retrieved on: 
Thursday, June 9, 2022
National Center for Advancing Translational Sciences, Aarhus University Hospital, Aarhus University, Degenerative disease, Autoimmune disease, CMO, Research, Autoimmunity, European Society of Radiology, CEO, Coronavirus Scientific Advisory Board (Turkey), IPC, MC2, All India Mahila Congress, Itchy, Maintenance, Multimedia, University, I&I, Therapy, Topical medication, Patient, Psoriasis, DDS, ESDR, MD, Family, CKD, Urea, Uremic pruritus, Skin, View, Dermatology, Hotel manager, Technology, Pharmaceutical industry, EU

COPENHAGEN, June 9, 2022 /PRNewswire/ -- MC2 Therapeutics A/S, a commercial stage pharmaceutical company, has named Lars Iversen, MD, DMSc an esteemed chair professor in dermatology at Aarhus University Hospital and at Aarhus University, its new full-time Chief Medical Officer (CMO) as of October 1st, 2022.

Key Points: 
  • COPENHAGEN, June 9, 2022 /PRNewswire/ -- MC2 Therapeutics A/S, a commercial stage pharmaceutical company, has named Lars Iversen, MD, DMSc an esteemed chair professor in dermatology at Aarhus University Hospital and at Aarhus University, its new full-time Chief Medical Officer (CMO) as of October 1st, 2022.
  • "Lars Iversen brings substantial experience and an extensive international network in the field of dermatology to the company," said Jesper J. Lange, CEO of MC2 Therapeutics.
  • Professor Lars Iversen has been a member of the International Psoriasis Council (IPC) board of directors since 2017.
  • Lars Iversen (Professor, MD, DMSc) is chair professor in dermatology at University of Aarhus since 2012.

Professor Lars Iversen joins MC2 Therapeutics as new Chief Medical Officer

Retrieved on: 
Thursday, June 9, 2022
National Center for Spinal Disorders, Aarhus University Hospital, Aarhus University, Degenerative disease, Autoimmune disease, CMO, Research, Autoimmunity, European Society of Radiology, CEO, Coronavirus Scientific Advisory Board (Turkey), IPC, MC2, All India Mahila Congress, Itchy, Maintenance, University, I&I, Therapy, Topical medication, Patient, Psoriasis, DDS, ESDR, MD, Family, CKD, Urea, Uremic pruritus, Skin, Dermatology, Hotel manager, Technology, Pharmaceutical industry, EU

COPENHAGEN, June 9, 2022 /PRNewswire/ -- MC2 Therapeutics A/S, a commercial stage pharmaceutical company, has named Lars Iversen, MD, DMSc an esteemed chair professor in dermatology at Aarhus University Hospital and at Aarhus University, its new full-time Chief Medical Officer (CMO) as of October 1st, 2022.

Key Points: 
  • COPENHAGEN, June 9, 2022 /PRNewswire/ -- MC2 Therapeutics A/S, a commercial stage pharmaceutical company, has named Lars Iversen, MD, DMSc an esteemed chair professor in dermatology at Aarhus University Hospital and at Aarhus University, its new full-time Chief Medical Officer (CMO) as of October 1st, 2022.
  • "Lars Iversen brings substantial experience and an extensive international network in the field of dermatology to the company," said Jesper J. Lange, CEO of MC2 Therapeutics.
  • Professor Lars Iversen has been a member of the International Psoriasis Council (IPC) board of directors since 2017.
  • Lars Iversen (Professor, MD, DMSc) is chair professor in dermatology at University of Aarhus since 2012.

Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients

Retrieved on: 
Thursday, April 28, 2022
Clinical, Hospital, U.S. Securities and Exchange Commission, LinkedIn, Nephrology, List of Hindawi academic journals, Iron, Outcome (probability), Association, Patient, Twitter, FDA, Risk, Kidney, Therapy, Chronic kidney disease, SIX Swiss Exchange, International Journal of Nephrology and Renovascular Disease, Private Securities Litigation Reform Act, Quality of life, Primary biliary cholangitis, Company, Annual report, Uremic pruritus, Security (finance), Marketing, Dialysis, Mortality, ISIN, Itch, Fresenius Medical Care, Vifor Pharma, Canadian International Council, Health, CKD, Atopic dermatitis, Instagram, Pharmaceutical industry, Health insurance

Vifor Pharma Group strives to help patients around the world with severe, chronic and rare diseases lead better, healthier lives.

Key Points: 
  • Vifor Pharma Group strives to help patients around the world with severe, chronic and rare diseases lead better, healthier lives.
  • For more information, please visit viforpharma.com
    Cara Therapeutics is an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus.
  • The Companys novel KORSUVA (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis.
  • 4 Mathur VS, et al.A longitudinal study of Uremic Pruritus in hemodialysis patients.Clin J Am Soc Nephrol.2010; 5(8):1410-1419.

Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients

Retrieved on: 
Friday, February 25, 2022
Risk, Outcome (probability), Clinical, Iron, Twitter, Canadian International Council, Primary biliary cholangitis, CKD, Security (finance), Atopic dermatitis, Association, SIX Swiss Exchange, Therapy, Chronic kidney disease, Company, Uremic pruritus, Private Securities Litigation Reform Act, Itch, International Journal of Nephrology and Renovascular Disease, Review, Nephrology, List of Hindawi academic journals, Vifor Pharma, Fresenius Medical Care, LinkedIn, Hospital, Dialysis, FDA, Instagram, EMA, Kidney, Patient, Marketing, Quality of life, ISIN, U.S. Securities and Exchange Commission, MAA, Mortality, Health, Pharmaceutical industry

Vifor Pharma Group strives to help patients around the world with severe, chronic and rare diseases lead better, healthier lives.

Key Points: 
  • Vifor Pharma Group strives to help patients around the world with severe, chronic and rare diseases lead better, healthier lives.
  • For more information, please visit viforpharma.com
    Cara Therapeutics is an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus.
  • The Companys novel KORSUVA (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis.
  • 4 Mathur VS, et al.A longitudinal study of Uremic Pruritus in hemodialysis patients.Clin J Am Soc Nephrol.2010; 5(8):1410-1419.

Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients

Retrieved on: 
Monday, February 28, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Risk, Canadian International Council, Security (finance), SIX Swiss Exchange, Therapy, Company, Uremic pruritus, Royal commission, Nephrology, Chronic kidney disease, Nasdaq, Private Securities Litigation Reform Act, Health, Outcome (probability), Iron, CKD, Atopic dermatitis, European Medicines Agency, U.S. Securities and Exchange Commission, Review, List of Hindawi academic journals, Itch, Fresenius Medical Care, Multimedia, Dialysis, Veni, vidi, vici, Quality of life, CHMP, MAA, Twitter, European, European Commission, Kidney, International Journal of Nephrology and Renovascular Disease, Vifor Pharma, LinkedIn, Hospital, EMA, Instagram, Patient, Union, Primary biliary cholangitis, Association, FDA, ISIN, Marketing, Mortality, Pharmaceutical industry, Medical device, EU

The CHMP opinion is the basis for the European Commissions final decision regarding marketing authorization for Kapruvia.

Key Points: 
  • The CHMP opinion is the basis for the European Commissions final decision regarding marketing authorization for Kapruvia.
  • If approved, Kapruvia will be the first therapy available in Europe for the treatment of chronic kidney disease-associated pruritus (CKD-aP) in hemodialysis patients.
  • We are pleased to have received the positive CHMP opinion, which brings us one step closer to making a treatment option available to hemodialysis patients in Europe who suffer from pruritus, said Christopher Posner, President and Chief Executive Officer of Cara Therapeutics.
  • These are major milestones on Cara Therapeutics path to being a category-defining leader in the treatment of pruritus.

The National Kidney Foundation to Doctors: Listen to Complaints of Itchy Skin

Retrieved on: 
Thursday, November 4, 2021
Linda, People, Uremic pruritus, Quality of life, Society, Obesity, American Society of Nephrology, National Kidney Foundation, Health care, Mount Sinai, Icahn School of Medicine at Mount Sinai, CKD, MD, Itch, Degenerative disease, Disease, NKF, Radar, Chronic kidney disease, White, Dialysis, Kidney disease, Patient, Itchy, Awareness, Hospital, Science, Risk factor, Death, ASN, Diabetes, Skin, Risk, Kidney failure, Medical device, Medicine, Tutoring, Pharmaceutical industry

This survey cohort of hemodialysis patients report near universal experience of itchy skin, with one in four characterizing their itch as "very" or "extremely intense."

Key Points: 
  • This survey cohort of hemodialysis patients report near universal experience of itchy skin, with one in four characterizing their itch as "very" or "extremely intense."
  • In the United States, 37 million adults are estimated to have kidney disease , also known as chronic kidney disease (CKD)and approximately 90 percent don't know they have it.
  • 1 in 3 adults in the U.S. are at risk for kidney disease.Risk factors for kidney disease include: diabetes , high blood pressure , heart disease , obesity , and family history.
  • The National Kidney Foundation (NKF) is the largest, most comprehensive, and longstanding patient-centric organization dedicated to the awareness, prevention, and treatment of kidney disease in the U.S. For more information about NKF, visit www.kidney.org .

Escient Pharmaceuticals Announces Positive Results from Phase 1 Study of EP547, an MrgprX4-Targeted Oral Therapy for Cholestatic and Uremic Pruritus

Retrieved on: 
Wednesday, July 14, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Organ systems, Medical specialties, Hepatology, Uremic pruritus, Cholestasis, Itch, Antipruritics, Nalfurafine, EP547 for Cholestatic and Uremic Pruritus, Escient Pharmaceuticals, EP547 FOR CHOLESTATIC AND UREMIC PRURITUS, ESCIENT PHARMACEUTICALS

The study found that EP547 was safe and well-tolerated in both healthy volunteers and patients with chronic cholestatic or kidney disease at all doses tested.

Key Points: 
  • The study found that EP547 was safe and well-tolerated in both healthy volunteers and patients with chronic cholestatic or kidney disease at all doses tested.
  • EP547 was found to be safe and well-tolerated with no serious adverse events, no adverse events leading to discontinuation, and no safety signals identified.
  • By blocking these pruritogens from activating MrgprX4, Escient believes EP547 has the potential to effectively treat both cholestatic and uremic pruritus.
  • Drug development to address cholestatic and uremic pruritus has been hampered by the lack of basic biological understanding of the relevant mechanisms.

VFMCRP and Cara Therapeutics announce European Medicines Agency has accepted to review the Marketing Authorization Application for difelikefalin

Retrieved on: 
Tuesday, March 30, 2021
Vifor Pharma, Uremic pruritus

Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives.

Key Points: 
  • Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives.
  • Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).
  • Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs.
  • 4 Mathur VS, et al.A longitudinal study of Uremic Pruritus in hemodialysis patients.Clin J Am Soc Nephrol.2010; 5(8):1410-1419.

Escient Pharmaceuticals Raises $77.5 Million Series B Round and Initiates a Phase 1/1b Clinical Trial of EP547, a MRGPR-targeted Therapy to Treat Cholestatic and Uremic Pruritus

Retrieved on: 
Monday, September 14, 2020
Biotechnology, Other Health, Health, Pharmaceutical, Clinical trials, Companies, CAC 40, Sanofi, Uremic pruritus, Cowen

The round was led by Sanofi Ventures and Cowen Healthcare Investments (CHI) with participation by new investors Redmile Group and Perceptive Advisors.

Key Points: 
  • The round was led by Sanofi Ventures and Cowen Healthcare Investments (CHI) with participation by new investors Redmile Group and Perceptive Advisors.
  • All of the companys existing investors, including The Column Group, 5AM Ventures, and Osage University Partners, participated in the round.
  • In just over two years since our launch, weve made significant progress developing our platform and pipeline.
  • Current treatment options for cholestatic and uremic pruritus are non-specific, largely ineffective, and have significant side effects, said Marcus F. Boehm, Ph.D., Chief Scientific Officer of Escient.

Pre & Post COVID-19 Market Estimates-Global Pruritus Therapeutic Market 2020-2024 | Evolving Opportunities with Abbott Laboratories and Allergan Plc | Technavio

Retrieved on: 
Monday, April 20, 2020
General Health, Pharmaceutical, Health, Cholestatic pruritus, Itch, Uremic pruritus, Cholestasis

The global pruritus therapeutic market is expected to grow by USD 3.63 billion as per Technavio.

Key Points: 
  • The global pruritus therapeutic market is expected to grow by USD 3.63 billion as per Technavio.
  • View the full release here: https://www.businesswire.com/news/home/20200420005385/en/
    Technavio has announced the latest market research report titled Global Pruritus Therapeutic Market 2020-2024 (Graphic: Business Wire)
    Read the 120-page report with TOC on "Pruritus Therapeutic Market Analysis Report by Type (Renal pruritus, Cholestatic pruritus, Hematologic pruritus, Endocrine pruritus, and Oncological pruritus), Geography (North America, Europe, APAC, and ROW), and the Segment Forecasts, 2020-2024".
  • In addition, the strong pipeline of expected launches is anticipated to boost the growth of the pruritus therapeutic market.
  • Its growing prevalence is providing significant growth opportunities for market vendors to engage in the development of novel pruritus therapeutics.